• Media
  • Careers
  • Contacts
CBP - Pioneering and developing Bi-targeting XDC technologyCBPCBPCBP

Pioneering and developing Bi-targeting XDC technology

Contacts
  • Who We Are
    • About CBP
    • Our Culture
    • Leadership
    • Our History
  • Science & Innovation
    • Approach
    • Platforms
    • World of Bi-XDC
  • Pipeline
    • Pipeline
    • Clinical Trials
    • Publications
  • For Patient
    • Patient Safety
    • Clinical Sites
    • Expanded Access Policy

Blog

Author By adminPosted on July 14, 2022April 10, 2024

AACR 2022|CBP to present study results of its leading candidate

The 2022 American Association for Cancer Research (AACR) annual meeting will be held from April 8 to 13, 2022 in New Orleans. Alon...
Read More
Author By adminPosted on July 14, 2022April 10, 2024

ASCO 2022|CBP-1008, first Bi-XDC, showcases its clinical data

● The preliminary clinical results showed that CBP-1008 has manageable safety profile. Evident antitumor activity was obser...
Read More
Author By adminPosted on March 31, 2022April 10, 2024

CBP announced CBP-1008 clinical data at 12th World ADC London

...
Read More
Author By adminPosted on March 24, 2022April 10, 2024

Coherent Biopharma will announce the update clinical process of the first clinical product CBP-1008 at 12th Annual World ADC London on March 29th

...
Read More
Author By adminPosted on July 9, 2021April 15, 2024

Coherent Biopharma received IND study may proceed letter (study permission) from US FDA for its bi-ligand drug conjugate CBP-1018

Coherent Biopharma’s another BESTTM(Bi-Engaging ligand-mediated Selective Targeting)platform pipeline investigational drug,...
Read More
Author By adminPosted on June 18, 2021April 10, 2024

CBP presented Phase Ia dose escalation study results of the first novel bi-specific ligand drug conjugate CBP-1008 in ASCO Annual Meeting

Coherent Biopharma (CBP) revealed Phase Ia clinical study results of the CBP-1008 in a poster presentation at the 2021 ASCO Annual...
Read More
Previous page 1 2 3 4 5 Next page

Categories

  • News 26

Recent Posts

  • The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1019February 23, 2025
  • The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1008October 12, 2024
  • Coherent Biopharma’s CBP-1019 has received Orphan Drug Designation from the FDA for three indicationsJune 26, 2024
  • ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attentionJune 5, 2024
  • 【AACR 2024】Coherent Biopharma Announced Latest Pipeline CBP-8008 Preclinical Research ProgressApril 10, 2024

Archives

  • 2025 (1)
  • 2024 (5)
  • 2023 (6)
  • 2022 (4)
  • 2021 (3)
  • 2020 (4)
  • 2019 (1)
  • 2018 (2)

Meet CBP

  • Leadership
  • Our History
  • Our Culture

Science&Innovation

  • Approach
  • Platforms
  • World of Bi-XDC

Pipeline

  • Pipeline
  • Clinical Trials
  • Publications

For Patient

  • Patient Safety
  • Clinical Sites
  • Expanded Access Policy
Copyright © 2025 CBP  All rights reserved.